Professor Tim Meyer

Job title

Consultant in medical oncology 

Qualifications

BSc MBBS PhD FRCP

GMC Number

3442074

Contact details

Phone number: 0207 794 0500 ext 36840

Email address: t.meyer@ucl.ac.uk

PA/secretary phone number: 020 7830 2601

PA/secretary email address: cedric.michael@nhs.net

Related services

Cancer services

Biography

Tim Meyer is professor of experimental cancer medicine at UCL and consultant in medical oncology. He specialises in the management of hepatocellular and neuroendocrine tumours and leads a large portfolio of clinical trials in these tumour types. He also runs a translational research program at the UCL Cancer Institute.

Publications

  • Meyer T, Wendi Q, Caplin ME, Armstrong G, Lao-Sirieix S-H, Hardy R, Valle JW, Talbot DC, Cunningham D, Reed N, Shaw A, Navalkissoor S, Luong T-V, Corrie PG. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer  2014; 50, 902– 911
  • Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Michaela S, Banck MS, Kanwar R, Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N , Hooshmand SM, Lauren K. Brais LK, Lawrence M, Trevor Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C, Grimsby J, Green L, Lennon L, Meyer T, Caplin C, Daniel C. Chung DC, Beutler AS, Ogino S, Thirlwell C, Shivdasani R, Sylvia L. Asa SL, Chris R, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors, Nat Genet. 2013 Dec;45(12):1483-6
  • Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D, Hackshaw A, Fox R,  Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial-embolisation for hepatocellular cancer Annals of Oncology 2013  Oct;24(10):2565-70
  • Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T  A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer. 2013 Mar 14;108(9):1838-45
  • Meyer T, Roughton M, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, O'Beirne J, Patch D, Burroughs A K. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization versus embolization alone for hepatocellular cancer. British Journal of Cancer 2013 108(6):1252-9
  • Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. J Clin Oncol 2013; 31:365-372
  • Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davies AH, Davar J, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toumpanakis C, Valle J, Verbeke C, Grossman AB, Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)  Gut  2012; 61(1):6-32
  • Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T,  EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol  2011; 55 (6):1309-1316
  • Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin ME, Meyer T, Circulating Tumour Cells and EpCAM Expression in Neuroendocrine Tumours. Clin Canc Res 2011; 17(2):337-45